CHRS
Coherus Oncology, Inc. NASDAQ Listed Nov 6, 2014$1.48
+6.47%
vs $1.39
Mkt Cap $178.1M
52w Low $0.72
42.4% of range
52w High $2.51
50d MA $1.65
200d MA $1.61
P/E (TTM)
-1.0x
EV/EBITDA
—
P/B
2.9x
Debt/Equity
0.7x
ROE
275.4%
P/FCF
-1.3x
RSI (14)
42.00
ATR (14)
$0.08
Beta
1.04
50d MA
$1.65
200d MA
$1.61
Avg Volume
1.2M
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
333 Twin Dolphin Drive · Redwood City, CA 94065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.36 | -0.34 | +4.3% | 1.93 | -3.6% | +1.0% | -8.7% | -5.1% | -3.6% | +1.8% | — |
| Nov 6, 2025 | AMC | -0.32 | -0.33 | -3.1% | 1.49 | -9.4% | -10.1% | -6.0% | +7.1% | +0.7% | -7.4% | — |
| Aug 7, 2025 | AMC | -0.31 | -0.34 | -9.7% | 0.88 | -1.1% | -7.1% | +7.2% | +4.0% | +9.1% | +2.1% | — |
| May 12, 2025 | AMC | -0.31 | -0.35 | -12.9% | 1.02 | -14.0% | -19.1% | -4.2% | -2.8% | -0.9% | +5.1% | — |
| Mar 10, 2025 | AMC | -0.10 | -0.28 | -180.0% | 1.04 | +0.0% | +1.0% | -6.7% | -9.1% | +3.3% | -0.5% | — |
| Nov 6, 2024 | AMC | -0.10 | -0.01 | +90.0% | 0.72 | +10.0% | +13.3% | -0.6% | -4.4% | +5.7% | -5.4% | — |
| Aug 8, 2024 | AMC | -0.21 | -0.14 | +33.3% | 1.29 | +12.4% | +10.9% | +2.1% | -1.4% | -4.9% | +13.1% | — |
| May 9, 2024 | AMC | -0.05 | -0.32 | -540.0% | 2.12 | +2.4% | -10.4% | +10.0% | -0.5% | +4.8% | -0.5% | — |
| Mar 13, 2024 | AMC | -0.21 | -0.62 | -195.2% | 2.30 | -8.7% | -5.7% | +2.3% | +0.0% | +10.4% | +1.2% | — |
| Nov 6, 2023 | AMC | -0.21 | -0.27 | -28.6% | 3.54 | -22.6% | -30.2% | -17.8% | -21.2% | -0.6% | +8.2% | — |
| Aug 2, 2023 | AMC | -0.52 | -0.38 | +26.9% | 4.34 | +9.4% | +17.7% | -0.8% | -1.0% | -4.6% | -4.2% | — |
| May 8, 2023 | AMC | -0.61 | -0.75 | -23.0% | 8.14 | -20.6% | -27.4% | +0.0% | -12.2% | -5.6% | -0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11 | Guggenheim | Initiates | Buy | $12 | $1.75 | $1.89 | +8.0% | +11.4% | -12.3% | +0.0% | -4.7% | -3.7% |
| Sep 4 | Maxim Group | Upgrade | Hold → Buy | — | $1.26 | $1.31 | +4.0% | +4.0% | -1.5% | +6.2% | -1.5% | -3.0% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.00 | -2.9% | -3.0% | +3.0% | +1.9% | +4.8% | -7.3% |
| Apr 24 | UBS | Maintains | Neutral → Neutral | — | $1.11 | $1.09 | -1.8% | -9.0% | +2.0% | +0.0% | -3.0% | +3.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.04 | +0.0% | +1.0% | -6.7% | -9.1% | +3.3% | -0.5% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.31 | $1.33 | +1.5% | -2.3% | -3.1% | -6.5% | -4.3% | +9.9% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.35 | +2.3% | -0.8% | -2.3% | -3.1% | -6.5% | -4.3% |
| Dec 5 | Baird | Maintains | Outperform → Outperform | — | $1.71 | $1.80 | +5.3% | -11.7% | +12.6% | +0.0% | -5.3% | +2.5% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.82 | +6.4% | +0.0% | -11.7% | +12.6% | +0.0% | -5.3% |
| Nov 8 | Baird | Maintains | Outperform → Outperform | — | $0.82 | $0.83 | +1.2% | -0.6% | -4.4% | +5.7% | -5.4% | -0.8% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.72 | $0.80 | +10.0% | +13.3% | -0.6% | -4.4% | +5.7% | -5.4% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.30 | $1.32 | +1.5% | -19.2% | -1.0% | +1.0% | +7.6% | -9.7% |
| Aug 16 | UBS | Downgrade | Buy → Neutral | — | $1.55 | $1.46 | -5.8% | -18.7% | +0.0% | -0.8% | +7.2% | -1.5% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.25 | -7.4% | -2.2% | +0.8% | -6.8% | +4.0% | +10.9% |
| Jul 1 | Baird | Maintains | Outperform → Outperform | — | $1.73 | $1.73 | +0.0% | -6.9% | -13.7% | +0.0% | -4.3% | -4.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $2.03 | +1.0% | -5.0% | -1.6% | -2.1% | +2.2% | -3.2% |
| May 13 | Truist | Maintains | Buy → Buy | — | $1.90 | $1.92 | +1.1% | +10.0% | -0.5% | +4.8% | -0.5% | -2.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.12 | $2.17 | +2.4% | -10.4% | +10.0% | -0.5% | +4.8% | -0.5% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.45 | $2.40 | -2.0% | +1.2% | +1.2% | -7.2% | -2.1% | +0.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.30 | $2.10 | -8.7% | -5.7% | +2.3% | +0.0% | +10.4% | +1.2% |
| Jan 23 | Baird | Maintains | Outperform → Outperform | — | $2.58 | $2.60 | +0.8% | -7.0% | -4.2% | +3.0% | -1.3% | -1.7% |
| Jan 23 | Truist | Maintains | Buy → Buy | — | $2.58 | $2.60 | +0.8% | -7.0% | -4.2% | +3.0% | -1.3% | -1.7% |
| Dec 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $3.00 | +37.6% | +23.4% | +20.4% | +2.8% | -5.7% | -3.8% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.30 | +0.4% | +0.4% | -3.5% | -5.0% | -0.9% | +13.4% |
| Nov 28 | Truist | Maintains | Buy → Buy | — | $1.94 | $1.91 | -1.5% | +8.8% | +3.3% | -2.3% | +8.0% | +0.0% |
| Nov 8 | Maxim Group | Downgrade | Buy → Hold | — | $2.47 | $2.48 | +0.4% | -17.8% | -21.2% | -0.6% | +8.2% | +5.8% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.54 | $2.74 | -22.6% | -30.2% | -17.8% | -21.2% | -0.6% | +8.2% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $3.54 | $3.48 | -1.7% | -10.0% | +2.7% | -11.2% | -5.7% | -3.6% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $4.05 | $4.00 | -1.2% | -1.7% | -0.3% | -2.5% | -3.4% | -3.7% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.05 | $4.00 | -1.2% | -1.7% | -0.3% | -2.5% | -3.4% | -3.7% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.34 | $4.75 | +9.4% | +17.7% | -0.8% | -1.0% | -4.6% | -4.2% |
| Jul 14 | Truist | Maintains | Buy → Buy | — | $4.27 | $4.33 | +1.4% | -4.9% | +7.6% | +0.5% | -0.2% | -4.8% |
| Jun 28 | Truist | Maintains | Buy → Buy | — | $3.84 | $3.84 | +0.0% | +5.5% | +3.5% | +1.9% | +3.5% | +3.4% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.13 | $4.17 | +1.0% | -7.0% | +0.8% | -2.1% | +5.3% | -4.5% |
| Jun 20 | Truist | Maintains | Buy → Buy | — | $4.13 | $4.17 | +1.0% | -7.0% | +0.8% | -2.1% | +5.3% | -4.5% |
| Jun 15 | Truist | Maintains | Buy → Buy | — | $5.36 | $5.36 | +0.0% | +0.6% | -23.4% | -7.0% | +0.8% | -2.1% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $5.00 | +0.4% | +5.8% | +2.1% | +0.2% | +0.6% | -0.7% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.09 | $4.17 | +2.0% | -1.0% | +9.9% | +11.9% | +5.8% | +2.1% |
| May 23 | Barclays | Maintains | Overweight → Overweight | — | $4.46 | $4.46 | +0.0% | +2.2% | -4.8% | -1.2% | +1.4% | -4.6% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.14 | $6.46 | -20.6% | -27.4% | +0.0% | -12.2% | -5.6% | -0.2% |
| May 1 | Truist | Maintains | Buy → Buy | — | $7.23 | $7.49 | +3.6% | +6.1% | -6.5% | +1.8% | +0.3% | +0.8% |
| Mar 28 | UBS | Upgrade | Neutral → Buy | — | $6.00 | $6.34 | +5.7% | +7.0% | +0.9% | -0.8% | +6.4% | +9.4% |
| Mar 8 | Barclays | Maintains | Overweight → Overweight | — | $7.30 | $7.25 | -0.7% | -5.5% | -9.6% | -2.7% | +4.9% | -0.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.77 | $6.53 | -3.5% | +7.8% | -5.5% | -9.6% | -2.7% | +4.9% |
| Nov 16 | Mizuho | Maintains | Buy → Buy | — | $7.96 | $7.88 | -1.0% | -7.7% | -8.7% | +0.4% | -2.1% | -0.8% |
| Nov 14 | JP Morgan | Maintains | Neutral → Neutral | — | $7.79 | $7.72 | -0.9% | +1.9% | +0.3% | -7.7% | -8.7% | +0.4% |
| Aug 16 | Mizuho | Maintains | Buy → Buy | — | $13.87 | $14.03 | +1.2% | -3.5% | -2.3% | -0.7% | -2.6% | -2.6% |
| Jun 14 | UBS | Maintains | Neutral → Neutral | — | $6.19 | $6.28 | +1.5% | -3.1% | -0.2% | -2.2% | +7.5% | +5.4% |
| May 20 | Mizuho | Maintains | Buy → Buy | — | $7.91 | $7.97 | +0.8% | +5.1% | -3.9% | -4.0% | -3.4% | +3.4% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $8.43 | $8.10 | -3.9% | -4.7% | +6.1% | -9.0% | -2.1% | +4.7% |
No insider trades available.
8-K
Coherus Oncology, Inc. -- 8-K Filing
Jun 1
8-K · 2.02
!! High
Coherus Oncology, Inc. -- 8-K 2.02: Earnings Results
Coherus Oncology reported quarterly earnings results, with detailed financial performance metrics available in the accompanying press release exhibit.
May 11
8-K
Coherus Oncology, Inc. -- 8-K Filing
Coherus Oncology doubled 2025 revenue to $40.8 million while slashing debt by 90% to $38.8 million, strengthening its balance sheet with $172.1 million in cash, indicating improved financial stability for investors.
Mar 9
8-K · 8.01
!! High
Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Coherus Oncology agreed to issue 28.6 million common shares to underwriters in a public offering, with underwriters granted a 30-day option to purchase additional shares.
Feb 17
8-K · 8.01
!! High
Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement
Coherus disclosed a material event that likely impacts near-term stock momentum; investors should monitor the announcement details for potential effects on clinical programs, partnerships, or financial guidance that could influence valuation.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 5,452,762 | $9M | New | Mar 2026 |
| 2 | Kohlberg Kravis Roberts & Co. L.p. | 3,036,076 | $4M | — | Dec 2025 |
| 3 | Two Sigma Investments, Lp | 2,302,001 | $4M | Added | Mar 2026 |
| 4 | Tang Capital Management Llc | 2,724,509 | $4M | Reduced | Dec 2025 |
| 5 | Alyeska Investment Group, L.p. | 2,250,000 | $4M | New | Mar 2026 |
| 6 | Cm Management, Llc | 2,100,000 | $3M | — | Dec 2025 |
| 7 | Panagora Asset Management Inc | 1,459,310 | $2M | Reduced | Mar 2026 |
| 8 | Propel Bio Management, Llc | 1,420,550 | $2M | New | Mar 2026 |
| 9 | Aqr Capital Management Llc | 1,206,046 | $2M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 913,800 | $2M | Added | Mar 2026 |
| 11 | Hudson Bay Capital Management Lp | 835,000 | $1M | Added | Dec 2025 |
| 12 | Vanguard Portfolio Management Llc | 604,525 | $1M | New | Mar 2026 |
| 13 | Ubs Group Ag | 547,209 | $925K | Reduced | Mar 2026 |
| 14 | Jane Street Group, Llc | 603,510 | $857K | Added | Dec 2025 |
| 15 | Sei Investments Co | 453,763 | $767K | Added | Mar 2026 |
| 16 | Morgan Stanley | 496,788 | $705K | Added | Dec 2025 |
| 17 | Invesco Ltd. | 335,309 | $567K | Reduced | Mar 2026 |
| 18 | Renaissance Technologies Llc | 331,700 | $561K | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 324,133 | $548K | Added | Mar 2026 |
| 20 | Millennium Management | 311,986 | $527K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$178.1M
Enterprise Value
$43.1M
P/E (TTM)
-1.02x
Forward P/E
—
PEG Ratio
0.00x
P/B
2.92x
P/S
4.22x
P/FCF
-1.29x
EV/EBITDA
—
Shares Out
120.4M
Financials (TTM)
Revenue
$42.2M
Net Income
-$170.3M
EBITDA
-$170.2M
Free Cash Flow
-$138.5M
Op Cash Flow
-$138.5M
EPS Basic
$-1.45
EPS Diluted
$-1.45
EPS Forward
$-0.96
Gross Margin
67.2%
Op Margin
-429.5%
Net Margin
-403.8%
Balance Sheet
Total Assets
$258.3M
Total Liab.
$197.3M
Total Equity
$61.0M
Cash
$172.1M
LT Debt
$37.1M
Book Value/Sh
$0.51
Debt/Equity
0.66x
Current Ratio
1.46
Quick Ratio
1.43
Returns & Growth
ROE
275.4%
ROA
65.0%
ROIC
-153.1%
Rev Growth YoY
-84.2%
EPS Growth YoY
-680.0%
Price Returns
2W
-2.5%
1M
-10.7%
3M
-4.8%
6M
+16.9%
12M
+104.1%
Technicals
52W High
$2.51
52W Low
$0.72
50d MA
$1.65
200d MA
$1.61
RSI (14)
42.00
ATR (14)
$0.08
Beta
1.04
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.02
High
$11.00
Low
$1.05
Median
$6.00
Data updated apr 25, 2026 1:17am
· Source: financialmodelingprep.com